#United States #New York #Pomerantz LLP #Nyxoah S.A. #FDA Announcement

Pomerantz Law Firm Investigates Potential Claims Against Nyxoah S.A.

On May 6, 2025, Pomerantz LLP announced that it is currently investigating claims on behalf of investors of Nyxoah S.A., a company listed on NASDAQ under the ticker symbol NYXH. This investigation aims to uncover whether Nyxoah and its officers or directors may have been involved in any acts of securities fraud or engaged in unlawful business practices that could negatively affect its investors.

The context for this investigation arose after a significant announcement from Nyxoah on March 25, 2025. The company reported that the U.S. Food and Drug Administration (FDA) issued an Approvable Letter regarding its Pre-Market Approval (PMA) application for the Genio® system, intended for treating obstructive sleep apnea. This letter indicated that while Nyxoah's application met the regulatory requirements, it was contingent on the successful completion of further reviews concerning the company's manufacturing processes and controls.

Following this announcement, market analysts expressed concerns that the commercial launch of Genio could face delays pending the completion of the FDA's additional review. As a consequence of this forecasted delay, Nyxoah's stock witnessed a considerable drop, plummeting $2.42 (or 21.36%) to close at $8.91 per share on March 26, 2025, signaling a potential loss for investors who had anticipated a sooner rollout of the product.

In light of these developments, Pomerantz LLP is reaching out to affect investors to ascertain their experiences and losses affiliated with Nyxoah's stock fluctuations. The firm is highly regarded in the field of corporate and securities litigation, having a long-standing history of advocating for investors impacted by corporate malpractice or financial misrepresentation.

The firm encourages Nyxoah investors who feel they may have suffered from these significant stock price changes to reach out to attorney Danielle Peyton at [email protected] or call 646-581-9980 ext 7980. There is also a mention of the possibility for affected investors to join a class action lawsuit as part of the investigation into Nyxoah's business practices.

Pomerantz LLP, founded by the late Abraham L. Pomerantz, is recognized as one of the premier firms specializing in class actions and securities litigation. Over the past 85 years, the firm has played a vital role in securing substantial financial recoveries for its clients and continues to champion the rights of victims of securities fraud and breaches of corporate governance.

Conclusion

As the situation unfolds, the outcome of Pomerantz's investigation could provide clarity for investors feeling uneasy about their positions in Nyxoah. As always in the volatile world of stocks and securities, it is crucial for investors to stay informed and consider the implications of regulatory announcements such as those from the FDA. This incident serves as a reminder of the intricate relationship between regulatory bodies and market dynamics, where a single announcement can have far-reaching consequences.